Donor Care & Management

6th edition of FACT-JACIE Standards

Kim Orchard
Consultant Haematologist
Director Wessex Blood and Marrow transplant Programme
University Hospital Southampton

6th edition



Published March 2015
Became effective on
June 1, 2015

JACIE joint accreditation committee
EBMT European Society for Blood and Marrow Transplantation
International Society for Cellular Therapy ISCT

5th vs 6th editions

6th Edition FACT-JACIE International Standards for Haematopoietic Cellular Therapy Product Collection, Processing and Administration

Summary of Changes

Available on JACIE website

Scope

- 5TH EDITION

INTERNATIONAL STANDARDS FOR CELLULAR THERAPY PRODUCT COLLECTION, PROCESSING, AND ADMINISTRATION

- 6TH EDITION

INTERNATIONAL STANDARDS FOR HEMATOPOIETIC CELLULAR THERAPY PRODUCT COLLECTION, PROCESSING, AND ADMINISTRATION

FACT-JACIE Standards



Clinical	Collection Marrow	Collection Apheresis	Processing
B1 General	CM1 General	C1 General	D1 General
B2 Clinical Unit	CM2 Marrow Collection Facility	C2 Apheresis Collection Facility	D2 Processing Facility
B3 Personnel	CM3 Personnel	C3 Personnel	D3 Personnel
B4 Quality Management	CM4 Quality Management	C4 Quality Management	D4 Quality Management
B5 Policies and Procedures	CM5 Policies and Procedures	C5 Policies and Procedures	D5 Policies and Procedures
B6 Allogeneic and Autologous Donor Selection, Evaluation, and Management	CM6 Allogeneic and Autologous Donor Evaluation and Management	C6 Allogeneic and Autologous Donor Evaluation and Management	D6 Equipment, Supplies, and Reagents
B7 Recipient Care	CM7 Coding and Labeling of Cellular Therapy Products	C7 Coding and Labeling of Cellular Therapy Products	D7 Coding and Labeling of Cellular Therapy Products
B8 Clinical Research	CM8 Process Controls	C8 Process Controls	D8 Process Controls
B9 Data Management	CM9 Cellular Therapy Product Storage	C9 Cellular Therapy Product Storage	D9 Cellular Therapy Product Storage
	CM10 Cellular Therapy Product Transportation and Shipping	C10 Cellular Therapy Product Transportation and Shipping	D10 Cellular Therapy Product Transportation and Shipping
			D11 Distribution and Receipt
			D12 Disposal
B10 Records	CM11 Records	C11 Records	D13 Records
	CM12 Direct Distribution to Clinical Program	C12 Direct Distribution to Clinical Program	

Definition

- Donor: A person who is the source of cells or tissue for a cellular therapy product.

- The term “donor” is used by these Standards even in the autologous setting because considerations for informed consent and suitability (i.e., safety) of the individual include issues above and beyond the individual’s status as a transplant patient.

Allogeneic and autologous donor evaluation and management

- **PART B: CLINICAL PROGRAM STANDARDS**
  - *B6.1 There shall be written criteria for allogeneic and autologous donor selection, evaluation, and management by trained medical personnel.*

- **PART CM: MARROW COLLECTION FACILITY STANDARDS**
  - *CM6.1 There shall be written criteria for allogeneic and autologous donor evaluation and management by trained medical personnel.*

- **PART C: APHERESIS COLLECTION FACILITY STANDARDS**
  - *C6.1 There shall be written criteria for allogeneic and autologous donor evaluation and management by trained medical personnel.*

Allogeneic **and** autologous donor selection, evaluation, and management

- These Standards are intended to promote the safety of the donor and recipient as well as the safety and efficacy of the cellular therapy product.

- For allogeneic donors, **all** the requirements in B6 apply, including standards to safeguard appropriate confidentiality, confirm histocompatibility matching, and help protect the recipient from the risks of transmissible disease.

- For autologous-only Clinical Programs, **many, but not all**, of the requirements in this section apply. The standards and substandards under B/CM/C6.1, B6.2, and B6.3 apply to autologous transplantation except for those that specify allogeneic donors only.

B/CM/C 6.1 There shall be written criteria for allogeneic and autologous donor selection, evaluation, and management by trained medical personnel

- The inspector may ask to verify compliance with donor selection SOPs by reviewing a specific donor evaluation.
- If a Clinical Program only performs allogeneic transplants, then the written criteria need only pertain to allogeneic donors.
- If a program performs only autologous transplants, then the written criteria need only reflect autologous donors.
- If the program performs both allogeneic and autologous transplants, then the criteria for both types of transplant must be written.

Written criteria for allogeneic donor selection, evaluation, and management

Criteria to include:

Criteria for the selection of allogeneic donors who are minors* or elderly**.

Criteria for the selection of allogeneic donors when more than one donor is available and suitable.

Information regarding the donation process should be provided to the potential allogeneic donor prior to HLA typing.

* Minor in UK <16yr; **no definition of 'elderly'

Examples of written criteria for allogeneic donors include:

- Infectious disease markers obtained within the appropriate time frame before collection for a donor.

- Criteria for an ineligible but acceptable donor (for example, an international donor may be ineligible but acceptable if all other donor criteria are fulfilled).

- The number of times a sibling donor can donate cells.

- The role of the donor advocate.

Allogeneic and autologous donor evaluation and management

- **B/CM/C6.2 ALLOGENEIC AND AUTOLOGOUS DONOR INFORMATION AND CONSENT FOR COLLECTION**
  - **Very important section and a common focus for inspections**
- **B/CM/C6.3 ALLOGENEIC AND AUTOLOGOUS DONOR SUITABILITY FOR CELLULAR THERAPY PRODUCT COLLECTION**
  - **Detailed SOPs often lacking in specifics**
  - **In the case of sibling donors or potential donors results of typing are the confidential results for the sibling.**

B/CM/C6.2 Donor rights

- Opportunity to ask questions and receive full information

- Right to refuse to donate

  - *B/CM/C6.2.5.1 Allogeneic donor shall be informed of the potential consequences to recipient of such refusal*

  - *B/CM/C6.2.8 The allogeneic donor shall give informed consent and authorisation prior to release of the donor's health or other information to recipient's physician and/or the recipient*

    - Results should be given confidentially to sibling

B6.2.1 Minimum donor information



B6.2.2/3 Translation / Interpretation

- Interpretation and translation shall be performed by individuals qualified to provide these services in the clinical setting.

- Family members and legally authorized representatives should not serve as interpreters or translators.

B6.2 Consent process

1. Consent from the allogeneic donor should be obtained by a licensed health care professional other than the intended recipient's primary health care professional

2. Donor shall give informed consent and authorization in advance to release the donor's health information to the transplant physician and/or the recipient as appropriate

3. Documentation of consent shall be available to the Collection Facility staff prior to the collection procedure

B6.2.9 Storage & discard policy

- The donor shall be informed of the policy for cellular therapy product discard or disposal, including actions taken when an intended recipient no longer requires the cellular therapy product.

Should be written information given to the donor

- Look for evidence in the patient information booklet, transplant discussion etc

B/CM/C6.4.1 Donor advocate



FOR WHOM?

To represent allogeneic donors who are:

- Minors

or

- Mentally incapacitated
- As defined by applicable laws

6th edition – now obligatory (“shall”)

B6.3.2 Risk evaluation

- Possible need for **central venous access**
- **Mobilization** therapy for collection of HPC, Apheresis
- **Anesthesia** for collection of HPC, Marrow
- **Pregnancy test**: within 7 days before mobilization/collection or initiating patient's preparative regimen (whichever occurs earliest)
- **Risk of hemoglobinopathy** prior to administration of the mobilization regimen

Risk of hemoglobinopathy

- *B6.3.3 / C6.3.3*

  The donor should be evaluated for the risk of hemoglobinopathy prior to administration of the mobilization regimen.

- Inspection Manual:

  Hemoglobinopathy risk assessment may include testing for the detection of Hemoglobin S (e.g. Sickle Dex) or an Hb-electropheresis test, but a test is not required i.e. not mandatory

C6.3.6 Test results communication

- The Clinical Program shall inform the Collection Facility and Processing Facility of donor test results or if any testing was not performed.

Look for evidence of communication

Donor follow-up

C6.3.9 There shall be a policy for follow-up of donors that includes routine management and the management of collection-associated adverse events.

B6.4 Additional requirements for allogeneic donors

B6.4.3 Allogeneic donors and allogeneic recipients shall be tested for ABO group and Rh type using two independently collected samples

B6.4.4. A red cell antibody screen shall be performed on allogeneic recipients

HLA typing

- Allogeneic donors and recipients shall be tested at a minimum for **HLA-A, B, DRB1** type by a laboratory accredited by **ASHI, EFI**, or equivalent. **HLA-C** testing shall be performed for **unrelated allogeneic donors** and related allogeneic donors other than siblings.

- DNA **high resolution molecular typing** shall be used for DRB1 typing.

- **Verification typing** shall be performed using an **independently sample** prior to allogeneic donor selection.

B6.4.6 Medical History & Risk Evaluation for Allogeneic Donors

- Vaccination
- Travel
- Blood transfusion
- Communicable disease
- Inherited conditions
- Hematological or immunological disease
- Malignant disease

B6.4.5 Disease testing



When?

Within thirty (30) days prior to collection

What?

- HIV type 1
- HIV type 2
- Hepatitis B virus
- Hepatitis C virus
- CMV (unless +)
- T.pallidum (syphilis)

Other:

If required by regulations:

(HTLV I/II, WNV, Chagas...)

Clinical Programs in EU member states are required to perform a risk assessment to determine if testing for HTLV I and II or other diseases is appropriate for their patient populations.

B6.4.13 Donor eligibility

Determined by a physician after review of:



Documented in the recipient's medical record <u>before</u>:

- Recipient's preparative regimen is initiated
- Allogeneic donor begins mobilization regimen

B6.4.13 Use of an <u>ineligible</u> allogeneic donor



Impact

ORIGINAL ARTICLE

The impact of improved JACIE standards on the care of related BM and PBSC donors

C Anthias[1,2], ME Ethell[3], MN Potter[3], A Madrigal[1,2] and BE Shaw[1,2,3]

"We observed significant improvements in donor consenting procedures … and donor follow-up … after stipulations in these areas were introduced"

EBMT transplant centers with FACT–JACIE accreditation have significantly better compliance with related donor care standards

Article · Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation 22(3) · November 2015